I-125 seed implantation improves the prognosis of pancreatic cancer patients treated with anti-PD-1 combined chemotherapy
10.3969/j.issn.1672-8467.2025.01.014
- VernacularTitle:I-125粒子植入改善接受抗PD-1联合化疗的胰腺癌患者的预后
- Author:
Ke MIN
1
;
Jia-ping JIANG
1
;
Wei-min WANG
1
;
Yun-fan WANG
1
;
Yue-hua TANG
1
;
Hong CHEN
1
;
Qiang YAO
1
;
Jun JIN
1
Author Information
1. 江苏大学附属宜兴医院肿瘤科 宜兴 214200
- Publication Type:Journal Article
- Keywords:
pancreatic cancer;
I-125 seed;
immunotherapy;
radiotherapy;
regulatory T cells(Treg)
- From:
Fudan University Journal of Medical Sciences
2025;52(1):107-113
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the prognosis and safety of patients with advanced pancreatic ductal adenocarcinoma(PDAC)who received I-125 seed implantation in treatment with anti-PD-1 monoclonal antibody+chemotherapy.Methods A retrospective analysis was conducted on patients with stage Ⅳ metastatic PDAC who received anti-PD-1 combined chemotherapy treatment at Yixing Hospital,Jiangsu University from Jan 2021 to Jun 2023.Patients were divided into two groups based on whether they received I-125 seed implantation:the I-125 seed implantation+anti-PD-1 monoclonal antibody+Chemotherapy group(IPC group)and the anti-PD-1 monoclonal antibody+chemotherapy group(PC group).The follow-up period ranged from 2 to 24 months,with a median follow-up time of 9 months.The prognosis of patients was analysed in combination with peripheral blood biomarkers.The peripheral lymphocyte subsets of patients in different treatment groups were preliminarily analysed by flow cytometry.Results A total of 13 patients were included,with 5 in the IPC group and 8 in the PC group.Progression-free survival(PFS)and overall survival(OS)in the IPC group were significantly longer than those in the PC group.The treatment in the IPC group was relatively safe,adverse reactions were controllable.The neutrophil-lymphocyte ratio(NLR)and CD4/CD8 ratio indicated that the prognosis of the IPC patients was better.The levels of regulatory T cells(Treg)and active regulatory T cells(aTreg)cells in the IPC patients were reduced after treatment compared with those of the PC patients.Conclusion The addition of I-125 seed implantation can improve the prognosis of patients with advanced PDAC who receive anti-PD-1 monoclonal antibody+chemotherapy,the post-treatment levels of patients'circulating aTreg cells are reduced,and the combination therapy has good safety.
